• Werewolf Therapeutics agreed to an all-stock merger with Ambros Therapeutics, creating a Nasdaq-listed company focused on neridronate for CRPS-1.
• Combined company to operate as Ambros Therapeutics, headquartered in San Diego, expected to trade under ticker AMBX.
• Transaction paired with an oversubscribed USD 150 million private placement, set to close concurrently with the merger.
• Financing expected to fund operations through CRPS-RISE Phase 3 topline results in 2028, planned NDA filing, cash runway into 1H 2029.
• Neridronate holds FDA Breakthrough Therapy, Fast Track, Orphan Drug designations; FDA alignment suggests one successful Phase 3 trial could support approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210800PRIMZONEFULLFEED9814095) on August 21, 2026, and is solely responsible for the information contained therein.